Get started
Work

Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)

Year: 2021
Type: article
DOI: 10.1016/s2152-2650(21)01393-8
Authors: Jan Burger, Paul Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steve Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Sandra Dai, Anita Szoke, James P. Dean, Thomas J. Kipps, Paolo Ghia
Institutions: The University of Texas MD Anderson Cancer Center, University of Rochester Medicine, University of Rochester, University of Calgary, Copernicus Memorial Hospital, Medical University of Lodz, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Rabin Medical Center, Leeds Teaching Hospitals NHS Trust, Stanford Medicine, Stanford University, King's College Hospital NHS Foundation Trust, Medical University of Silesia, Royal Bournemouth Hospital, Jiangsu Province Hospital, Ghent University Hospital, Universitat Autònoma de Barcelona, Hospital de Sant Pau, Pharmacyclics (United States), University of California San Diego, Moores Cancer Center, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: closed
OpenAlex ID: W4200249206
FWCI:
Cites:
Cited by:
Related to: 10